TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01118091

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD8 enriched Young TIL
Description: Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10\^9 to 2x10\^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x 10\^8) and the administration of high-dose aldesleukin.
Study: NCT01542099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml.
Study: NCT01522495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Imaging
Description: SPY Imaging to assess tissue perfusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Imaging
Description: SPY Imaging to assess tissue perfusion
Study: NCT01458145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minding the Baby Home Visiting Program
Description: Weekly home visits for one year followed by bi-weekly home visits until child is 24 months of age provided to young at risk families by a team of nurse practitioner and social worker home visitors
Study: NCT02096536

Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin
Description: vancomycin administration based on decision of treating physician
Study: NCT00816270

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Upper eyelid blepharoplasty
Description: Bilateral upper lid blepharoplasty was performed on each patient by the same experimented surgeon using a standard technique. One side (right or left upper eyelid) was randomly chosen for experimental closure with liquid bandage and the opposite eyelid served as the control being used a 6/0 nylon continuous sutures.
Study: NCT00704834

Intervention type: OTHER
Intervention: Blood Draw
Description: 35 cc of peripheral blood will be obtained by venipuncture from each subject.

Intervention type: OTHER
Intervention: Blood Draw
Description: 35 cc of peripheral blood will be obtained by venipuncture from each subject.
Study: NCT01015443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide
Description: Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 918 microgram (mcg) of tecemotide (L-BLP25) at Week 1, 2, 3, 4, 5, 6, 7, and 8 (primary treatment phase) and then at 6-Week intervals, beginning at Week 14 (maintenance phase) until disease progression (PD) is documented or the subject discontinues for any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single low dose cyclophosphamide
Description: A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first administration of tecemotide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 8 consecutive weekly subcutaneous vaccinations of tecemotide (L-BLP25) matching placebo at Week 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance treatment at 6-Week intervals, beginning at Week 14, until PD is documented or the subject discontinues for any other reason.
Study: NCT04050709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: PD-L1 t-haNK Suspension for Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: PD-L1 t-haNK Suspension for Infusion
Study: NCT01877954

Intervention type: DRUG
Intervention: Extra-fine hydrofluoroalkane beclometasone dipropionate

Intervention type: DRUG
Intervention: Fluticasone propionate
Study: NCT03017287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoMe App
Description: Assessment of the the GlucoMe App
Study: NCT01708525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy Water
Description: A tissue labeling model via the consumption of the stable isotope, deuterated water (heavy water). Heavy water consumed over the course of the 6-week study period for a direct kinetic measure of in vivo collagen synthesis. 60 ml (about 12 teaspoons) of heavy water (also called deuterated water or 2H2O), was consumed three times a day for the first five days. Starting on Day 6, two 60 ml doses of heavy water were consumed per day for the remaining 37 days.
Study: NCT02579733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01260389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmaceutical care intervention
Description: Pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
Study: NCT04263506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vignette with emphasis on supervisor's opinion
Description: A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without the description of supervisor's advice that does not oppose to detrimental research practice (i.e. the supervisor is fine with whatever the PhD student decides in the dilemma).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vignette with emphasis on supervisor's opinion
Description: A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without the description of supervisor's advice that does not oppose to detrimental research practice (i.e. the supervisor is fine with whatever the PhD student decides in the dilemma).
Study: NCT04163991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: liquid for IV infusion following dilution in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: liquid for IV infusion following dilution in normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline for IV infusion
Study: NCT01015443

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A single IV infusion of 0.9 percent (%) sodium chloride (saline) will be given 3 days before first placebo vaccination.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: The BSC will be provided as per the investigator's discretion, and is not limited to palliative radiation, psychosocial support, analgesics and nutritional support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: The BSC will be provided as per the investigator's discretion, and is not limited to palliative radiation, psychosocial support, analgesics and nutritional support.
Study: NCT03887832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMBI digital app
Description: Digital platform on the smartphone for the media package

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: media package
Description: The SMBI app contains a \<1 minute video of a mother and baby or just mother, a reflection question about the video, a few questions about their mood and stress, and some prompts and suggestions on what to do if they have problems.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard newborn and infant care
Description: Recommended standard pediatric primary care will be provided for infants up to 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard newborn and infant care
Description: Recommended standard pediatric primary care will be provided for infants up to 6 months.
Study: NCT03790735

Intervention type: DIAGNOSTIC_TEST
Intervention: FISH
Description: Targeted chromosomal aberrations detection
Study: NCT00796783

Intervention type: DRUG
Intervention: Cushing's syndrome confirmation
Study: NCT02464319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hrIL-2 active
Description: 1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hrIL-2 placebo
Description: 1 million U doses of placebo s.c. injection active group: placebo group =1:1
Study: NCT03339427

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: different doses of vitamin D supplementation

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: control group
Study: NCT01900548

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein (HPHL)
Description: The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein (HPLL)
Description: The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (P)
Description: Will not be given protein but the same energy content using maltodextrin (in a blended fashion).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
Study: NCT01446653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing plus feedback
Description: Provides an MI + feedback intervention supplemented with video and brochures-based information

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Video arm will provide information via documentary video

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Brochure
Description: Informational Brochures are given to participants following baseline assessment.
Study: NCT03849989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Skin biopsy:~Tissue samples will be taken by punch biopsy according to the daily routine of the Department of Dermatology of the Maastricht UMC+.~Steps:~* Skin desinfection with chlorhexidine digluconate 1% solution~* Local anaesthesia with lidocaine hydrochloride 1%~* Biopsy specimens are taken with sterile punch device (disposable biopsy punch delivered by kai medical)~* Biopsy specimens are retrieved with sterile pincer and cut with sterile blade~* Wound is stitched with a single transcutaneous stich using absorbable suture (vicryl 4.0).~* Wound will be treated with R/ fusidic acid ointment 3 to 5 times per day for two weeks~* In the first week after laser therapy the wound will be covered by R/ Urgotull non-adhesive gauze, R/ Cutisoft cotton non-sterile gauze and R/ Klinipress exsupad absorbing bandage.
Study: NCT02337946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Study: NCT00350506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 64 Channel VCT
Study: NCT01421901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Ertapenem i.v,m 1g, once a day, 3 days
Study: NCT04692051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel + Cisplatin
Description: Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Cisplatin
Description: Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
Study: NCT03682081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isometric tongue strengthening facilitated by Iowa Oral Performance Instrument (IOPI)
Description: An air-filled pressure bulb is placed on the surface of the oral tongue and pressed against the hard palate during exercise. Each patient is given a target pressure value to aim for as determined by the baseline one repetition maximum (1RM) lingual pressures. During week one of the regimen, the target value of each repetition will be 60% of the 1RM. For the remaining seven weeks, the target value will be increased to 80% of the 1RM. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isometric tongue strengthening facilitated by Iowa Oral Performance Instrument (IOPI)
Description: An air-filled pressure bulb is placed on the surface of the oral tongue and pressed against the hard palate during exercise. Each patient is given a target pressure value to aim for as determined by the baseline one repetition maximum (1RM) lingual pressures. During week one of the regimen, the target value of each repetition will be 60% of the 1RM. For the remaining seven weeks, the target value will be increased to 80% of the 1RM. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene Oral Balance Gel
Description: Participants will be instructed to apply an amount equivalent to about 1 cm of Biotene® Oral Balance Gel with a finger to the tongue and most intensely affected areas of the oral cavity three times a day after brushing their teeth for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene Oral Balance Gel
Description: Participants will be instructed to apply an amount equivalent to about 1 cm of Biotene® Oral Balance Gel with a finger to the tongue and most intensely affected areas of the oral cavity three times a day after brushing their teeth for 8 weeks.
Study: NCT04266795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Venetoclax tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine IV or SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine IV or SC injection.
Study: NCT02988960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous
Study: NCT01900548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
Study: NCT03020186

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity+ MED diet
Study: NCT02988960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intratumoral
Study: NCT03020186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity+green MED diet
Description: \*\*\*\*Sub-study from all 3 main arms: Autologous fecal microbiota supplement intervention derived from the time of maximal weight loss: At the 6-month time period, the time of anticipated greatest weight reduction, participants's feces samples will be processed to capsulized inocula. Samples will be frozen within 2 hours and will be kept at -80c pending analysis. Participants will be randomized to receive either research capsules or identical placebo capsules between 8 and 14 months time period. Placebo capsules will consist of a combination of powdered cocoa and vegetable gelatin in normal saline/glycerol and will be identical in appearance to research capsules.
Study: NCT01103050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAV680 + Cetirizine Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAV680 + Cetirizine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine + QAV680 Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QAV680 Placebo + Cetirizine Placebo
Study: NCT00650585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project ALERT
Description: Project ALERT (Adolescent Learning Experiences in Resistance Training) is a drug prevention curriculum designed for middle-school students (11 to 14 years old). The 11 lessons in the first year and 3 booster lessons in the second year focus on alcohol, tobacco, marijuana, and inhalants - the substances that adolescents are most likely to use. Project ALERT uses participatory activities and videos to help motivate youth to avoid drug use, to teach youth skills and strategies to resist peer pressures to use drugs, and to establish social norms against drug-use. More information about Project ALERT may be found at http://www.projectalert.best.org/.
Study: NCT00816218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: pioglitazone, 45 mg daily
Study: NCT03855254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: communication type
Description: Positive and negative communication types are the way that the practitioner communicates to the participant about the potential effectiveness of the osteopathic treatment. The control is a neutral communication condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: communication type
Description: Positive and negative communication types are the way that the practitioner communicates to the participant about the potential effectiveness of the osteopathic treatment. The control is a neutral communication condition.
Study: NCT04293250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compare the severity of postoperative pain of the physical activity group Vs non-physical activity group
Description: Compare postoperative pain scores for the physical activity Vs non-physical activity group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compare the severity of postoperative pain of the physical activity group Vs non-physical activity group
Description: Compare postoperative pain scores for the physical activity Vs non-physical activity group
Study: NCT03270085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam
Description: Colesevelam (Welchol) is approved by the Food and Drug Administration (FDA) for the treatment of high blood cholesterol levels and to treat type 2 diabetes however, Colesevelam is not approved for the use proposed in this study and is considered investigational.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo looks exactly like the study drug, but it contains no active ingredient. This is used to learn if the effects seen in research participants are truly from the study drug.
Study: NCT05068804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: The participants in the cooling trial put cold towels on their forehead and neck for 3 min in the shaded dugout during their offensive half innings when they were not scheduled to hit or on base. Each participant received the cooling intervention 3 to 4 times in each game. After each use, the towels were kept in a cooler that contained water mixed with ice and salt to keep the temperature at approximately 0℃.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: The participants in the control trial sat in the shaded dugout without any cooling intervention.
Study: NCT01144637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE®
Description: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE®
Description: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE®
Description: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 ml TBS
Study: NCT00722176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-1020
Description: 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-1020 10-30 mg
Description: BL-1020 10-30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: risperidone
Study: NCT03426969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT01421901

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendectomy